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Abstract: The functions of the annexin family of proteins involve binding to Ca2+, lipid membranes,
other proteins, and RNA, and the annexins share a common folded core structure at the C terminus.
Annexin A11 (AnxA11) has a long N-terminal region, which is predicted to be disordered, binds RNA,
and forms membraneless organelles involved in neuronal transport. Mutations in AnxA11 have been
linked to amyotrophic lateral sclerosis (ALS). We studied the structure and stability of AnxA11 and
identified a short stabilising segment in the N-terminal end of the folded core, which links domains I
and IV. The crystal structure of the AnxA11 core highlights main-chain hydrogen bonding interactions
formed through this bridging segment, which are likely conserved in most annexins. The structure
was also used to study the currently known ALS mutations in AnxA11. Three of these mutations
correspond to buried Arg residues highly conserved in the annexin family, indicating central roles in
annexin folding. The structural data provide starting points for detailed structure–function studies of
both full-length AnxA11 and the disease variants being identified in ALS.
Keywords: annexin A11; crystal structure; solution structure; calcium binding; membrane binding;
protein stability; folding; amyotrophic lateral sclerosis
1. Introduction
The annexin (Anx) family of Ca2+-binding proteins is widely distributed in eukaryotes, with
twelve Anxs found in vertebrates [1–3]. All Anxs share multiple structural elements, most notably
an evolutionarily conserved C-terminal Anx core. This core consists of four similar domains, each
comprised of ~70 amino acids arranged into five α helices, termed A–E [1,4]. The only exception is
AnxA6, which contains eight domains, most likely due to a fusion of duplicated anxA5 and anxA10
genes [5]. The five helices within each domain are connected via short loops, forming a right-handed
superhelix. Helices A and B as well as helices D and E are oriented pairwise in an antiparallel fashion,
while helix C is positioned as a bridge orthogonally to the others [4]. The loops connecting helix A to
helix B and helix D to helix E contain the Ca2+ binding sites [1,6].
The Anxs are structurally distinct from the EF-hand and C2-domain Ca2+-binding proteins [2].
They reversibly bind negatively charged lipids in a Ca2+-dependent manner, which is a defining
feature of this protein family [1]. The binding is mediated through the convex side of the core structure,
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coupled to a conformational change induced by Ca2+ binding [1,2]. Through lipid binding, Anxs can
affect important proteolipid membrane properties, such as curvature and phase separation [7,8].
While the folded C-terminal core structure of the vertebrate Anxs is conserved, the structure of the
N terminus varies greatly between different Anxs and determines their individual properties [1]. This
region typically contains 10–30 residues, but AnxA7 and AnxA11 harbour unusually long N termini.
AnxA11 has the longest N-terminal domain of all Anxs, with ~200 residues [9]. The N termini of
AnxA7 and AnxA11 resemble each other, both being hydrophobic, enriched in Gly, Tyr, and Pro [10–12].
The Ca2+-dependent interaction of AnxA11 with phosphatidylserine changes the conformation of its
N terminus [13]. Furthermore, the AnxA11 N terminus interacts with the apoptosis-linked gene-2
protein (ALG-2) [14] and S100A6 (calcyclin) [15].
Rabbit AnxA11 appears to exist as two isoforms; AnxA11A and AnxA11B [16]. Only the
former binds S100A6 in the presence of Ca2+ via the region Gln49-Thr62. This region is absent in
AnxA11B [16–18], suggesting isoform-specific functions. S100A6 binds to AnxA1 and AnxA2 in
addition to AnxA11 [19,20], indicating functional overlap between these three proteins. According
to the UniProt database [21], human AnxA11 is predicted to have two isoforms due to alternative
splicing (UniProt ID P50995), leading to a truncation of 33 residues in the N terminus of the shorter
form, while rat AnxA11 only exists as a single isoform corresponding to the longer human isoform
(UniProt ID Q5XI77).
In certain cell types, AnxA11 is predominantly localised in the cytoplasm, while in others, it is
mainly present in the nucleus [15,22]. It is likely that the A isoform is enriched in the nucleus, whereas
the B isoform is specifically localised to the cytoplasm [16]. The N terminus was suggested to be
responsible for the nuclear localisation [18,23]. In the nucleus, AnxA11 appears to be involved in
events related to the cell cycle. It participates in cytokinesis, playing an essential role in the formation
of the midbody. Cells lacking AnxA11 cannot complete cytokinesis and undergo apoptosis [24].
Expression levels of AnxA11 have been linked to various cancers [25–30]. Recent studies have
revealed that mutations in AnxA11 play an important role in the development of the neurodegenerative
disease amyotrophic lateral sclerosis (ALS) [8,31–37]. The molecular basis of these mutations is unclear,
as an experimentally determined 3D structure of AnxA11 has been lacking.
Since the long N terminus of AnxA11 renders recombinant production of the protein challenging,
N-terminally truncated recombinant forms were generated, and the crystal structure of one form,
∆188AnxA11, was determined. We show that a 4-residue sequence motif in the N terminus of the core
structure, conserved in most Anxs, functions as a Velcro-like bridging segment and is important for the
thermal stability of the Anx core structure. The currently known ALS mutations are analysed based on
the crystal structure, providing a view into conserved features of the Anx core fold.
2. Materials and Methods
2.1. Cloning of Full-Length and N-Terminally Truncated Forms of AnxA11
In order to obtain full-length rat AnxA11, reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed using total RNA isolated from PC12 cells by the Trizol
method [38]. The cDNA of AnxA11 was obtained using the iScript kit (Bio-Rad, Hercules,
CA, USA) according to the manufacturer’s instructions and the forward primer 5′-ATCCGG
CCATGGGTATGAGCTATCCAGGCTATCCAC-3′ (NcoI restriction site is underlined) and the
reverse primer 5′-ATCCGGGGTACCTCAGTCGTTGCCACCACAGATC-3′ (Acc65I restriction site is
underlined). The anxA11 cDNA was digested with NcoI and Acc65I, purified after separation in a 1%
agarose gel, and ligated into the same restriction sites of the pETM10 vector (a kind gift from Gunter
Stier, Heidelberg). Two truncated versions of AnxA11 were generated by PCR using the pETM10
plasmid harbouring rat full-length anxA11 cDNA as a template and using the same reverse primer as
for full-length AnxA11. The forward primers were 5′-ATCCGGCCATGGGTAGAGGCACCATCA-3′
and 5′-ATCCGGCCATGGGTACCGATGCTTCTG-3′ (the NcoI restriction site is underlined), resulting
Biomolecules 2020, 10, 660 3 of 17
in ∆188AnxA11 (starting with 189-RGTI) and ∆192AnxA11 (starting with 193-TDAS), respectively.
Both constructs code for the tag sequence MLHHHHHHPMG at the N terminus. The cDNAs were
ligated into the pETM10 vector after digestion of PCR fragments with Acc65I and NcoI. Constructs
were verified by DNA sequencing.
2.2. Expression and Purification of Full-Length and N-Terminally Truncated Forms of AnxA11
E. coli BL21(DE3) cells were transformed with AnxA11 expression plasmids. The bacteria were
grown in 5 mL lysogeny broth (LB) medium with 50 µg/mL kanamycin until an OD600 of 0.6, after
which 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce protein expression
at +25 ◦C for 4 h or at +15 ◦C overnight (ON), to determine optimal expression conditions. At the
end of protein expression, 1 mL of the culture was withdrawn and centrifuged at 2000× g for 10 min
at +4 ◦C. The supernatant was discarded, and the pellet was resuspended in 500 µL lysis buffer
(50 mM Na2HPO4, 500 mM NaCl, 5% (v/v) glycerol, 10 mM imidazole) containing 0.5 µg/mL DNase
I (Sigma, St. Louis, MO, USA), 0.25 µg/mL RNase A (Sigma, St. Louis, MO, USA), and cOmplete
EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland). The samples were sonicated on ice,
whereafter 100-µL aliquots (total lysate) were withdrawn. Additional 100-µL aliquots of the lysates
were transferred into new tubes and centrifuged at 21,000× g for 15 min at +4 ◦C. The supernatant was
withdrawn. The pellet was resuspended in 100 µL lysis buffer. After addition of denaturation buffer,
20 µL of the protein samples were separated on 4–20% SDS-PAGE (Mini-PROTEAN TGX Precast
Protein Gels, Bio-Rad, Hercules, CA, USA) at 20 mA and 250 V as the limiting voltage.
For large-scale purification, the above procedure was repeated using 300 mL LB medium.
The full-length (FL) and N-terminally truncated AnxA11 were induced at +25 ◦C for 4 h, while
FL-AnxA11 was also expressed ON at +15 ◦C. The cells were collected by centrifugation at 4000× g for
15 min. The pellets were frozen at −80 ◦C in lysis buffer before the addition of 0.5 µg/mL DNase I,
0.25 µg/mL RNase A, and cOmplete EDTA-free protease inhibitor cocktail (Roche, Basel, Switzerland).
Subsequently, cells were broken by sonication, and the lysates were centrifuged at 16,000× g for 30 min
at +4 ◦C. All purification steps were performed at +4 ◦C.
We took advantage of an N-terminal His-tag to purify AnxA11, which reduces degradation at the
N terminus [13]. Purification using Co2+-NTA gave higher yields than Ni2+-NTA resin. The lysate
supernatant was loaded onto a Co2+-NTA agarose column and incubated for 30 min with gentle
rotation. Subsequently, the proteins on the Co2+ resin were washed with equilibration buffer (50 mM
Na2HPO4, 0.3 M NaCl, 10 mM imidazole; pH 8) and high-salt buffer (50 mM Na2HPO4, 1 M NaCl,
10 mM imidazole; pH 8), both buffers containing EDTA-free protease inhibitors. Elution buffer (50 mM
Na2HPO4, 0.3 M NaCl, 250 mM imidazole; pH 8) containing EDTA-free protease inhibitors was used
to elute the proteins. After adding EGTA to a final concentration of 2 mM, the eluates were quickly
transferred onto PD-10 columns for a buffer exchange to 20 mM Tris (pH 8). All recombinant forms
of AnxA11 were subjected to size exclusion chromatography using a Superdex 75 or 200 Increase
10/300 GL column (GE Healthcare, Chicago, IL, USA). Protein concentration was determined by
absorbance at 280 nm (using molecular masses of 55513, 36828, and 36401 Da and sequence-based
extinction coefficients of 42750, 13410, and 13410 M−1 cm−1 for full-length AnxA11, ∆188AnxA11, and
∆192AnxA11, respectively). The protein size and purity were confirmed by SDS-PAGE and Coomassie
Brilliant Blue staining.
2.3. Circular Dichroism Spectroscopy
A Jasco J-810 spectropolarimeter (Jasco, Hampshire, UK) with a Peltier temperature control unit
was used for far-UV circular dichroism (CD) spectroscopy. Melting curves were recorded from +25
to +75 ◦C at 222 nm, at a heating rate of 40 ◦C/h, to determine the thermal transition temperature
(Tm). Tm was estimated in GraphPad Prism 7 (GraphPad, San Diego, CA, USA) using four-parameter
logistic regression.
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Synchrotron radiation CD (SRCD) data were acquired from 0.5 mg/mL ∆188AnxA11 and
∆192AnxA11 in 20 mM Tris-HCl, pH 8.0, on the AU-CD synchrotron beamline at ASTRID2 (ISA,
Aarhus, Denmark). Samples containing 1 mM CaCl2 were included in addition to CaCl2-free samples
to detect Ca2+-induced changes in the secondary structure content. Closed 100-µM circular cells were
used (Suprasil, Hellma Analytics, Müllheim, Germany). Spectra were recorded from 170 to 280 nm at
+10 ◦C. Baselines were subtracted, and CD units were converted to ∆ε (M−1 cm−1) in CDtoolX 1.06 [39].
The spectra were truncated based on the HT voltage and the CD spectrum noise levels.
2.4. Small-Angle X-Ray Scattering
SAXS data were collected from 0.41–2.96 mg/mL ∆188AnxA11 and ∆192AnxA11 in 20 mM
Tris-HCl on the EMBL/DESY P12 beamline, PETRA III (Hamburg, Germany) [40] (Figure S1). Protein
samples at 0.7–1.0 mg/mL were then studied with 0–1 mM CaCl2 to follow potential oligomerisation.
Monomeric bovine serum albumin (66.5 kDa) was used as a molecular weight standard. Data were
processed and analysed using the ATSAS package 2.8.4 [41], and GNOM 5.0 was used to calculate
distance distribution functions [42]. Theoretical scattering of the crystal structure was calculated and
fitted against the SAXS data using CRYSOL 2.8.3 [43]. Ab initio modelling was performed using
GASBOR 2.3i [44]. SUPCOMB 2.3 [45] was used for crystal structure and ab initio model superposition.
SAXS data collection, processing, and fitting parameters are presented in Table 1.
Table 1. Small-angle X-ray scattering parameters and analysis.
Data Collection Parameters
Instrument P12, PETRAIII, DESY
Wavelength (nm) 0.124
Angular range (nm−1) 0.022–7.33
Exposure time (s) 0.045
Exposure temperature (◦C) 10
Protein AnxA11∆188 AnxA11∆192
Concentration range (mg/mL) 0.77–2.96 0.41–1.18
Structural Parameters
I0 (relative) [from Guinier] 0.02759 0.0274
Rg (nm) [from Guinier] 2.44 ± 0.13 2.43 ± 0.20
I0 (relative) [from P(r)] 0.02692 0.02748
Rg (nm) [from P(r)] 2.500 ± 0.016 2.503 ± 0.019
Dmax (nm) [from GNOM] 10.00 9.97
VPorod (nm3) [from GNOM] 58.03 59.53
Molecular Mass Determination
Molecular mass Mr (kDa) [from I0 using Guinier] 1 34.3 34.1
Molecular mass Mr (kDa) [from I0 using P(r)] 1 33.5 34.2
Molecular mass Mr (kDa) [from VPorod] 34.1 35.0
Molecular mass Mr (kDa) [from absolute scale] 34.8 34.8
Theoretical Mr from sequence (kDa) 36.8 36.4
Software
Primary data reduction & processing PRIMUS
Ab initio modelling GASBOR
χ2 0.770 0.629
Fitting of theoretical scattering curve to data CRYSOL
χ2 0.888 0.749
1 Monomeric BSA standard was used as reference (Mr = 66.5 kDa; I0 = 0.0534).
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2.5. Protein Crystallisation, Data Collection, and Structure Determination
Sitting-drop vapour diffusion crystallisation experiments were set up in 96-well format. X-ray
diffraction data were collected on the EMBL P13 beamline, PETRA III (Hamburg, Germany) [46]
from a crystal grown in 100 mM Bis-tris (pH 5.5), 3 M NaCl at +20 ◦C; the drop contained 150 nL of
12.7 mg/mL ∆188AnxA11 and 150 nL of reservoir solution. The crystal was cryoprotected by adding
a solution containing 25% glycerol and 75% reservoir solution directly onto the crystallisation drop.
Upon mounting, the crystal was flash-frozen in liquid N2, and it was kept at 100 K during X-ray
diffraction data collection.
Diffraction data were processed with XDS [47], and the structure was solved by molecular
replacement in Phaser 2.8.3 [48] with PDB entry 1ANN (bovine AnxA4) as a search model [49].
Refinement was carried out using phenix.refine 1.18 [50], and model building with coot 0.8.9.1 [51].
The structure quality was assessed with MolProbity [52]. The data processing and refinement statistics
are presented in Table 2.





Unit cell parameters a = 39.1 Å, b = 86.7 Å, c = 87.3 Å
α = 114.0◦, β = 102.0◦, γ = 97.2◦
Resolution range (Å) 50–2.30 (2.36–2.30) 1
Completeness (%) 95.4 (95.0)
Reflections total/unique 141110/42245 (9818/3046)
〈I/σI〉 5.2 (1.1)
Rsym (%) 17.5 (164.0)
Rmeas (%) 20.9 (196.6)
CC1/2 (%) 99.2 (47.6)
redundancy 3.3 (3.2)
Data Processing
Rcryst/Rfree (%) 22.8 (26.6)
Rmsd bond length (Å) 0.002
Rmsd bond angle (◦) 0.4
MolProbity score (percentile) 1.58 (98th)
Ramachandran
favoured/disallowed (%) 97.2/0.3
1 Numbers in parentheses refer to the highest-resolution shell.
For structure analysis, the programs PyMOL 2.3.2 [53] and its APBS [54] plugin were used.
The refined AnxA11 crystal structure, along with the experimental structure factors, was deposited at
the PDB with the entry code 6TU2.
3. Results and Discussion
3.1. Solubility Assays, Large-Scale Expression, and Purification of the N-Terminally Truncated Forms of
AnxA11
We studied recombinant rat AnxA11, which is nearly identical to the human AnxA11 (Figure 1A).
Induction was performed at +25 ◦C for 4 h and at +15 ◦C ON to determine optimal expression
conditions. There was little or no difference in yield between the two modes of expression. FL-AnxA11
was consistently more challenging to express than its truncated forms, yielding remarkably low
concentrations, and it was notoriously prone to aggregation, as reported previously [13]. The solubility
of the truncated forms of AnxA11 in bacterial lysates was assessed after centrifugation at 21,000× g
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by comparing samples from the total bacterial lysate with the corresponding supernatant and pellet
by SDS-PAGE (Figure 1B). Two N-terminally truncated versions of AnxA11 were designed, cloned,
expressed, and purified, namely, ∆188AnxA11 and ∆192AnxA11. Previously, we noticed by sequence
alignment that a segment of ~10 residues in the N terminus preceding the first α helix of domain I is
highly conserved in Anxs [55]. In addition, the N-terminal residues that immediately precede the core
domain have been suggested to stabilise the overall structure of AnxA2 [55,56].
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(A) Sequence alignment between rat and human AnxA11. (B) Uninduced (U), total (T), supernatant
(S), and pellet (P) fractions of bacterial lysates containing ∆188AnxA11 or ∆192AnxA11 as indicated.
(C) 10 µL of FL-AnxA11 and the N-terminally truncated forms ∆188AnxA11 and ∆192AnxA11, purified
using Co2+-resin. Molecular mass standards are indicated to the right. Proteins ere separated in 10
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segment [8] or mis olding of the protein in bacterial cells.
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3.2. Thermal Stability of the N-Terminally Truncated ∆188AnxA11 and ∆192AnxA11
To address thermal stability, ellipticity at 222 nm was monitored as a function of temperature
for ∆188AnxA11 and ∆192AnxA11. The thermal transition temperatures were estimated from the
inflection points of the melting curves (Figure 1D). The Tm of FL-AnxA11 was earlier reported to be
+45 ◦C [13]. The Tm of ∆188AnxA11 showed a Tm of +50.76 ± 0.02 ◦C, while that of ∆192AnxA11
was substantially lower (+41.87 ± 0.02 ◦C). This difference highlights the importance of the four
amino acid residues 189-RGTI-192 in thermally stabilising the core structure of AnxA11. Cooperative
unfolding of the two truncated forms of AnxA11 remained largely unchanged but decreased slightly
in ∆192AnxA11. This increased thermal stability of ∆188AnxA11 compared to ∆192AnxA11 may
explain why we obtained crystals of ∆188AnxA11, but not of the other N-terminally truncated form.
The dramatic difference in Tm is necessarily accounted for by at least one of the four additional residues
present in ∆188AnxA11 being involved in the stabilising of the core structure.
3.3. The Crystal Structure of AnxA11
Using ∆188AnxA11, we solved the crystal structure of the rat AnxA11 core domain. The asymmetric
unit contains three molecules of AnxA11, and the structure presents the canonical Anx core fold.
The Ca2+ binding sites are partially occupied, whereby two monomers have three Ca2+ ions bound,
and one monomer has four (Figure 2). As is typical for the Anxs, all Ca2+ binding sites are on one face
of the molecule, promoting calcium-dependent lipid membrane binding (Figure 2).
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Figure 3. Rat annexins and conservation of the RGTI otif. (A) The N-terminal Velcro-like bridging
segment is shown in surface mode, bound to domain IV. (B) Stereo view of the hydrogen bonding
interactions of the motif with three helices in domain IV. (C) Sequence alignment of all rat Anxs.
The N-terminal motif is underlined in blue, and the mutations (red) and variants (green) linked to ALS
are shown with asterisks. A6 and A6c correspond to the N- and C-terminal halves of AnxA6.
Comparisons with other Anxs show that the segment 189–192 is a conserved motif in the Anx
family. The only Anx that does not contain the motif at the sequence level is AnxA13; conservation is
weak for AnxA1 and AnxA8. The 4-residue segment forms conserved interactions with the ends of
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helices in domain IV (Figure 3B). These interactions are mainly comprised of main-chain hydrogen
bonds, which explains the mode of conservation and the importance of the Gly residue in the motif.
Interestingly, it has been proposed that AnxA11 is the common ancestor of all mammalian Anxs [57],
except for AnxA7 and AnxA13—the two phylogenetically oldest Anxs [58]. Thus, the AnxA11 core
domain has the highest similarity to the other mammalian Anxs, acting as a sort of prototype [59].
The PhosphoSite database lists a number of phosphorylation sites for Anxs, most of which come
from high-throughput assays [60]. AnxA11 is phosphorylated, but the exact sites remain unknown [15].
Interestingly, the well-characterised Tyr23 and Ser25 phosphorylation sites of AnxA2 lie within the
4-residue bridging region (Figure 3C). Phosphorylation at Tyr23 and Ser25 results in a closed or open
conformation, respectively, of AnxA2 [56]. Similarly, a phosphomimicking mutation in Thr6 of AnxA4
results in an opening of the structure [61], hinting at a general mechanism of Anx conformation
regulation through phosphorylation of the RGTI motif. A comparison of the structures of AnxA11,
AnxA2, and AnxA4 is presented in Figure 4. Of other Anxs, AnxA6 has a phosphorylation site in the
bridging segment [62]. These findings can be understood based on the conserved structure of the
observed bridging segment. The regulation of this segment through post-translational modification
may be a general means to regulate overall conformation and dynamics of Anxs, possibly resulting in
altered binding to functional ligands, such as RNA or membranes.
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electrostatic potential. The view from the Ca2+-binding face. Ca2+ ions are shown as green spheres.
The negative sites (red) are the locations for Ca2+ binding, and their neutralization will make the
surface very positive, enabling lipid membrane binding. (B) The opposite face of AnxA11 is relatively
featureless. (C) Superposition of AnxA11 (coloured) with the AnxA5 trimer (gray) [64]. Superposition
was done based on one monomer (bottom right) to better highlight possible differenc s in assembly.
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One might assum that AnxA11 would arrange on a membrane much like t does in the crystal; the
N-terminal segments would then point away from the membrane. This is in line with the observations that
AnxA11 induces membrane curvature [7], as well as the suggestion that the N terminus of AnxA11 binds
to RNA, while the core structure binds to lipids in lysosomes for long-distance co-transport in neurons [8].
The RNA binding site in AnxA2 has been shown to reside within domain IV [70]. The binding dynamics
were recently investigated; AnxA2 binds strongly to an RNA 8-mer (5′-GGGGAUUG-3′) with a Kd of 30
nM [71]. The RNA binding sites in AnxA11 have not been determined.
3.4. Structure-Based Analysis of ALS Disease Mutations
The crystal structure of rat AnxA11 allows one to analyse the structural basis of AnxA11 mutations
linked to amyotrophic lateral sclerosis (ALS) [35] in humans. The sequence identity between full-length
rat and human AnxA11 is 93.3%, being 96.5% for the core structure. The identification of AnxA11
as an ALS gene is rather recent, and mutations are being continuously identified. Thus, it is safe to
assume that more ALS mutations will be identified in the future. We studied the mutations thus far
linked to ALS with respect to potential structural implications. Many of the mutations, including the
best-characterised D40G [35], lie in the N-terminal extension, which is not present in the crystallised
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construct. The mutations in this region could affect protein–protein interactions, protein localisation,
phase separation, or binding to mRNA [8]. More interesting for the current structural study, however,
are the mutations identified within the Anx core domain.
Five mutations have thus far been described in ALS patients within the AnxA11 core: S229R, R235Q,
R302C, R346C, and G491R; in addition, G189E is located two residues before the start of the crystallised
rat AnxA11 construct [35,37]. In the 3D structure, the AnxA11 mutations can be observed clustered at two
locations (Figure 6A). Interestingly, three of these mutations involve a buried Arg residue, and a close look
at the alignment reveals that these Arg residues are fully conserved in all rat Anxs. The remaining two
mutations replace an exposed, non-conserved, small residue with an Arg. Details of the environment
of each of the three conserved Arg residues are shown in Figure 6B–D. In brief, two of them coordinate
carbonyl groups at C termini of helices, and one is involved in a conserved extended buried network of
salt bridges between domains II and IV. These locations suggest that the ALS mutations involving these
conserved Arg residues will have effects on AnxA11 folding and/or stability.
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Figure 6. Location of ALS mutations and variants in the AnxA11 structure. (A) The five ALS mutations (see
text) are highlighted in red and the two rare variants in green. The two 3D clusters of mutations/variants
are shown with blue dashed circles. One cluster lies in domain II, possibly affecting folding and/or
interactions with domain III. The other cluster is at the interface between domains I and IV, i.e., the N and C
terminus of the AnxA11 core structure. (B) Arg233 (corresponding to the human R235Q mutation) makes
four contacts to carbonyl groups at the C-terminal end of domain I helices B and E. With its buried positive
charge, Arg233 interacts with the negative h lix dipole from both helices. (C) Arg344 (corresponding to
R346C) similarly caps helix B of domain III. (D) An exten ed salt bridge network exists between domains II
(top) and IV (b ttom) (stere view). Arg300 (corresponds to R302C) is central in this net ork. The charged
residues with numbers indicated are fully conserved in all rat Anxs (Arg, blue; acidic, red).
∆∆G predictions for the five mutations on the SDM server [72] indicate decreased stability for
all mutations except S229R. Hence, the affected residues may be important for correct folding and/or
stability of AnxA11. Recent functional characterisation of the AnxA11 ALS mutation R235Q shows
that the mutant protein is prone to aggregation and sequesters FL-AnxA11. This in turn abolishes the
binding to calcyclin [35]. In addition, two rare missense variants, A293V and I307M, were recently
discovered in the Chinese Han population [34]. These residues are located in domain II (Figure 6).
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The N-terminal tail of AnxA11 has a unique amino acid composition, reminiscent of disordered
proteins able to undergo liquid–liquid phase separation (LLPS) [73]. It has the hallmarks of an extended
segment poised for π-π interactions, which are central in LLPS [74]. Indeed, the AnxA11 N-terminal
region was recently shown to promote LLPS; its N terminus binds to RNA granules, which do not
contain membranes, while the core structure binds to lipids in membranes [8]. The effects of this
phase separation on the stability of the AnxA11 core domain are currently unknown. Furthermore,
ALS-associated mutations in both the N terminus (D40G) and C terminus (R346C) of AnxA11 were
shown to promote phase transition from liquid–liquid droplets to more stable gel-like states within
AnxA11 droplets and in addition impair the reversal of the states. As a consequence, these mutations
disrupt the function of AnxA11 to tether RNA granules with lysosomes [8].
3.5. The Solution Behaviour of the AnxA11 Core
The thermal stability difference between ∆188AnxA11 and ∆192AnxA11 prompted us to study their
conformation in solution using SAXS and SRCD. In SAXS, both variants were monomeric with identical
distance distributions and globular folds that superposed well with the crystal structure (Figure 7A–E),
indicating that the absence of the RGTI stretch does not lead to large-scale conformational changes. Despite
the trimeric packing in the crystal, AnxA11 is monomeric in solution under the employed conditions.
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Similarly to most Anxs, AnxA11 has been implicated in Ca2+ binding [1,13]. Structural studies of
many Anxs have revealed Ca2+ binding to the convex side of the core structure, essentially through
coordination by acidic residues. To test for effect of Ca2+ on the folding of the core structure of AnxA11,
we titrated ∆188AnxA11 and ∆192AnxA11 with CaCl2 in SAXS and followed the radius of gyration
(Rg; Figure 7F). The Rg of both truncated proteins remained the same up to 1 mM CaCl2. Additionally,
we carried out SRCD spectroscopy of ∆188AnxA11 and ∆192AnxA11 in the absence and presence of
1 mM CaCl2 (Figure 7G). The spectral quality was excellent, with the data being truncated at 178 nm.
The presence of Ca2+ did not alter the spectra, indicating that Ca2+ does not influence the secondary
structure content of the core structure. This result confirms that ∆192AnxA11 is folded despite its
dramatic decrease in thermal stability, and that the degree of secondary structure content between the
two variants is nearly identical. Ca2+ induced a large thermal stabilisation of FL-AnxA11, indicated by
a rise in Tm of ~14 ◦C [13]. The presence of up to 75 mM Ca2+ only induced small increases in AnxA11
α-helical content [13]. Thus, Ca2+ binding results in only local conformational changes, which primes
AnxA11 for lipid membrane binding.
4. Conclusions
As the diversity of the vertebrate Anx family is mainly realised through the uniqueness of the
N-terminal tail [1,16,75,76], many functional features are lost by truncation. However, crucial functional
properties of interest, such as mRNA binding, Ca2+-dependent binding to phospholipids, as well as
Ca2+ binding itself, may be retained. Thus, truncated Anxs may serve as a foundation for functional
studies, dodging practical issues often encountered due to their long N termini.
The crystal structure of AnxA11, although similar to known Anx core domain structures, provides
important starting points to further understand the structure–function relationships in AnxA11 and
other Anx family members. The identification of a strongly stabilizing Velcro-like bridging segment
at the N terminus of the Anx core, as well as the fact that many known ALS mutations correspond
to highly conserved buried Arg residues in the Anx fold, provide new insights into Anx folding.
AnxA11, like many other ALS targets, is part of a membraneless organelle, a ribonucleoprotein complex,
involved in neuronal transport of mRNA granules [8,77–79]. It is evident that this process can be
affected by mutations in either the N-terminal region or the folded core domain of AnxA11, which in
turn can affect binding to RNA, lipid membranes, and Ca2+. The fact that the bridging segment is a
target for regulatory phosphorylation in AnxA2 shows that in addition to simply stabilizing the core
structure, this segment may be a conformational switch common to most Anxs.
Supplementary Materials: The following are available online at http://www.mdpi.com/2218-273X/10/4/660/s1,
Figure S1: ∆188AnxA11 and ∆192AnxA11 SAXS dilution data.
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